A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT03954067. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced/Metastatic Solid Tumors
Study identification
- NCT ID
- NCT03954067
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- ASP9801 Biological
- Pembrolizumab Combination Product
Biological · Combination Product
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2, 2019
- Primary completion
- Apr 18, 2024
- Completion
- Apr 18, 2024
- Last update posted
- Apr 21, 2025
2019 – 2024
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| University of Arizona - Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| The Angeles Clinic and Research Institute | Los Angeles | California | 90025 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| University of Kentucky, Markey Cancer Center | Lexington | Kentucky | 40536 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40241 | — |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68130 | — |
| Roswell Park Cancer Institute - Medical Oncology | Buffalo | New York | 14263 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15260 | — |
| Mary Crowley Cancer Research Center | Dallas | Texas | 75251 | — |
| The University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| UVA Cancer Center | Charlottesville | Virginia | 22903 | — |
| VCU Massey Cancer Center | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03954067, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2025 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03954067 live on ClinicalTrials.gov.